334 related articles for article (PubMed ID: 35141049)
1. Cancer immunomodulation using bispecific aptamers.
Thomas BJ; Porciani D; Burke DH
Mol Ther Nucleic Acids; 2022 Mar; 27():894-915. PubMed ID: 35141049
[TBL] [Abstract][Full Text] [Related]
2. Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective.
Vandghanooni S; Eskandani M; Barar J; Omidi Y
J Mol Med (Berl); 2018 Sep; 96(9):885-902. PubMed ID: 30056527
[TBL] [Abstract][Full Text] [Related]
3. Aptamers: A Feasible Technology in Cancer Immunotherapy.
Soldevilla MM; Villanueva H; Pastor F
J Immunol Res; 2016; 2016():1083738. PubMed ID: 27413756
[TBL] [Abstract][Full Text] [Related]
4. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
Foffi G; Pastore A; Piazza F; Temussi PA
Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
[TBL] [Abstract][Full Text] [Related]
5. Clinical applications of nucleic acid aptamers in cancer.
Pei X; Zhang J; Liu J
Mol Clin Oncol; 2014 May; 2(3):341-348. PubMed ID: 24772298
[TBL] [Abstract][Full Text] [Related]
6. Bispecific antibodies in cancer immunotherapy.
Dahlén E; Veitonmäki N; Norlén P
Ther Adv Vaccines Immunother; 2018 Feb; 6(1):3-17. PubMed ID: 29998217
[TBL] [Abstract][Full Text] [Related]
7. Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers.
Yu Y; Liang C; Lv Q; Li D; Xu X; Liu B; Lu A; Zhang G
Int J Mol Sci; 2016 Mar; 17(3):358. PubMed ID: 26978355
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy progress and prospects: RNA aptamers.
Que-Gewirth NS; Sullenger BA
Gene Ther; 2007 Feb; 14(4):283-91. PubMed ID: 17279100
[TBL] [Abstract][Full Text] [Related]
9. Aptamer-Based Probes for Cancer Diagnostics and Treatment.
Hu X; Zhang D; Zeng Z; Huang L; Lin X; Hong S
Life (Basel); 2022 Nov; 12(11):. PubMed ID: 36431072
[TBL] [Abstract][Full Text] [Related]
10. Oligonucleotide aptamers: Recent advances in their screening, molecular conformation and therapeutic applications.
Xiao X; Li H; Zhao L; Zhang Y; Liu Z
Biomed Pharmacother; 2021 Nov; 143():112232. PubMed ID: 34649356
[TBL] [Abstract][Full Text] [Related]
11. Are BiTEs the "missing link" in cancer therapy?
Suryadevara CM; Gedeon PC; Sanchez-Perez L; Verla T; Alvarez-Breckenridge C; Choi BD; Fecci PE; Sampson JH
Oncoimmunology; 2015 Jun; 4(6):e1008339. PubMed ID: 26155413
[TBL] [Abstract][Full Text] [Related]
12. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM
Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012
[TBL] [Abstract][Full Text] [Related]
14. Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus.
Tang J; Ma X; Chen X; Feng M; Jin X; Wang K; Wan J; Zhu X; Xie R; Dong S; Hu S; Jiang H; Xie C
Ann Transl Med; 2022 Jul; 10(14):805. PubMed ID: 35965796
[TBL] [Abstract][Full Text] [Related]
15. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
16. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
17. Novel Human Bispecific Aptamer-Antibody Conjugates for Efficient Cancer Cell Killing.
Passariello M; Camorani S; Vetrei C; Cerchia L; De Lorenzo C
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31470510
[TBL] [Abstract][Full Text] [Related]
18. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.
Curigliano G; Criscitiello C; Esposito A; Fumagalli L; Gelao L; Locatelli M; Minchella I; Goldhirsch A
Breast; 2013 Aug; 22 Suppl 2():S96-9. PubMed ID: 24074802
[TBL] [Abstract][Full Text] [Related]
19. Aptamers against extracellular targets for in vivo applications.
Pestourie C; Tavitian B; Duconge F
Biochimie; 2005; 87(9-10):921-30. PubMed ID: 15963620
[TBL] [Abstract][Full Text] [Related]
20. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
